RegulatoryGuideline · draft

FDA Issues Draft Guidance on Single BLAs for Individualized Genome Editing Products

🇺🇸 FDA · Wed 28 Oct 2026

The agency's draft guidance sets out how an individualized genome editing product with several variants can be covered by one Biologics License Application, including after licensure.

The US Food and Drug Administration has announced a draft guidance titled "Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management". The document was published on 28 October 2026.

According to the agency, the draft sets out recommendations on how an individualized human genome editing (GE) product that includes multiple product variants can be submitted in a single Biologics License Application (BLA).

Once finalised, the guidance will reflect the FDA's current thinking on several points. These include how sponsors should specify the extent of variation in the GE component within a BLA, and how new product variants can be added to the BLA after licensure. The agency also indicates that related topics will be covered.

The full text of the draft was not available when this article was prepared, so details of the specific recommendations are not reported here. As a general point, draft guidance documents are non-binding and are normally issued for public comment before the FDA completes them.

What it means for your team

  • Sponsors developing individualized GE therapies should review the draft to see how a single BLA could cover several product variants.
  • Regulatory teams should note that the guidance addresses both the initial definition of GE component variation and the later addition of variants after licensure, which bears on lifecycle planning.
  • Because the document is a draft, teams may wish to consider submitting comments to the FDA and should expect the recommendations to evolve before finalisation.

Official guideline text: FDA ↗

Article written by VigiEye from the official source (FDA). AI-assisted; check the source before acting.

More Regulatory All →